Evidence map›Paper›PMID 31721643›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2020

Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features.

Bradley A McGregor, Rana R McKay, David A Braun, Lillian Werner, Kathryn Gray, Abdallah Flaifel, Sabina Signoretti, Michelle S Hirsch, John A Steinharter, Ziad Bakouny and 10 more

Registry-linked trialOpen access · bronzeAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02724878 (Phase II Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma), which is not on this map. Cited by 82 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed, 6 pooled it
14.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02724878 phase2completednot on this map

Phase II Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma

TypeinterventionalSponsorDana-Farber Cancer InstituteRan2016 to 2024Enrolled65ConditionsAdvanced Non-Clear Cell Kidney CancerArmsBevacizumab, Atezolizumab
3 · Its place in the literature

Who cites it

82 citing papers in PubMed, 6 syntheses or guidelines pooled it, 143 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021
    Guideline
  6. Pooled it
  7. Trial
  8. Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Trial
  9. Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022
    Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Review
  15. Article
  16. Review
  17. Article
  18. Molecularly defined renal cell carcinomas.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2026
    Review
  19. Review
  20. Current Evidences and Future Perspectives in the Management of Metastatic Non-Clear Cell Renal Cell Carcinoma.International journal of urology : official journal of the Japanese Urological Association · 2025
    Review

22 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 1 country.

Bradley A McGregorDana-Farber Cancer Institute, Boston, MA.
Rana R McKayMoores Cancer Center, La Jolla, CA.
David A BraunDana-Farber Cancer Institute, Boston, MA.
Lillian WernerDana-Farber Cancer Institute, Boston, MA.
Kathryn GrayDana-Farber Cancer Institute, Boston, MA.
Abdallah FlaifelDana-Farber Cancer Institute, Boston, MA.
Sabina SignorettiDana-Farber Cancer Institute, Boston, MA.
Michelle S HirschDana-Farber Cancer Institute, Boston, MA.
John A SteinharterDana-Farber Cancer Institute, Boston, MA.
Ziad BakounyDana-Farber Cancer Institute, Boston, MA.
Ronan FlippotDana-Farber Cancer Institute, Boston, MA.
Xiao X WeiDana-Farber Cancer Institute, Boston, MA.
Atish ChoudhuryDana-Farber Cancer Institute, Boston, MA.
Kerry KilbridgeDana-Farber Cancer Institute, Boston, MA.
Gordon J FreemanDana-Farber Cancer Institute, Boston, MA.
Eliezer M Van AllenDana-Farber Cancer Institute, Boston, MA.
Lauren C HarshmanDana-Farber Cancer Institute, Boston, MA.
David F McDermottBeth Israel Deaconess Medical Center, Boston, MA.
Ulka VaishampayanKarmanos Cancer Institute, Detroit, MI.
Toni K ChoueiriDana-Farber Cancer Institute, Boston, MA.
Dana-Farber Cancer Institute · USBeth Israel Deaconess Medical Center · USMoores Cancer CenterThe Barbara Ann Karmanos Cancer Institute · US

Funding

Tumor Biology and Microenvironment (Program 1)P30CA022453 · NCI · WAYNE STATE UNIVERSITY · PI Julie Lynn Boerner · 1985 to 2026
$68.4M
NCI NIH HHS P30 CA022453
6 · The paper itself

Abstract

purposeIn this multicenter phase II trial, we evaluated atezolizumab combined with bevacizumab in patients with advanced renal cell carcinoma (RCC) with variant histology or any RCC histology with ≥ 20% sarcomatoid differentiation. PATIENTS AND

methodsEligible patients may have received previous systemic therapy, excluding prior bevacizumab or checkpoint inhibitors. Patients underwent a baseline biopsy and received atezolizumab 1,200 mg and bevacizumab 15 mg/kg intravenously every 3 weeks. The primary end point was overall response rate (ORR) by RECIST version 1.1. Additional end points were progression-free survival (PFS), toxicity, biomarkers of response as determined by programmed death-ligand 1 (PD-L1) status, and on-therapy quality-of-life (QOL) metrics using the Functional Assessment of Cancer Therapy Kidney Symptom Index-19 and the Brief Fatigue Inventory.

resultsSixty patients received at least 1 dose of either study agent; the majority (65%) were treatment naïve. The ORR for the overall population was 33% and 50% in patients with clear cell RCC with sarcomatoid differentiation and 26% in patients with variant histology RCC. Median PFS was 8.3 months (95% CI, 5.7 to 10.9 months). PD-L1 status was available for 36 patients; 15 (42%) had ≥ 1% expression on tumor cells. ORR in PD-L1-positive patients was 60% (n = 9)

conclusionIn this study, atezolizumab and bevacizumab demonstrated safety and resulted in objective responses in patients with variant histology RCC or RCC with ≥ 20% sarcomatoid differentiation. This regimen warrants additional exploration in patients with rare RCC, particularly those with PD-L1-positive tumors.

Indexed as

AdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenBevacizumabCarcinoma, Renal CellFemaleHumansImmunohistochemistryKidney NeoplasmsMaleMiddle AgedNeoplasm StagingProspective StudiesAntibodies, Monoclonal, HumanizedatezolizumabB7-H1 AntigenBevacizumabCD274 protein, human

Identifiers

PMID31721643
PMCPMC7051851
OpenAlexW2988263178

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.